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Background: Associations between breast cancer and thyroid disorders are reported in numerous studies.
Relationships between thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and breast cancer have
been previously demonstrated. However, no analysis has been performed concerning an association between
thyrotropin (TSH) receptor antibodies (TSHRAb) and breast cancer. The aim of the study was to evaluate the
prevalence of breast cancer or benign breast tumors in patients with Graves’ disease and to analyze a possible
relationship between Graves’ disease and these two groups of breast diseases with emphasis to epidemiology and
laboratory findings.
Patients and methods: Clinical and laboratory details of 2003 women hospitalized for endocrine disorders were
retrospectively analyzed, using an unpaired Student’s t-test, logistic regression analysis, χ2 test of independence or
the two-sided ratio comparison test.
Results: The coexistence of Graves’ disease and breast cancer was statistically significant. We observed TSHRAb and
TgAb more frequently in patients with breast cancer. We found that TSHRAb is the only variable possessing
predictive value for breast cancer.
Conclusions: The strong relationship between Graves’ disease and breast cancer is proposed. We suggest that
TSHRAb could be described as a positive determinant of breast cancer. The present data call attention to the
usefulness of screening for breast cancer in long-term follow-up of patients with autoimmune thyroid disorders,
especially of those with Graves’ disease. Similarly, screening for autoimmune thyroid disorders should be performed
in patients with nodular breast disease. Additionally, the article draws ideas for further research in order to develop
targeted treatment for more successful outcome in patients with breast cancer.
Keywords: Breast cancer, Thyroid, Autoimmune disease, Graves’ disease, TSH receptor antibody, TSH, Thyroglobulin
antibody, Thyroperoxidase antibodyIntroduction
Breast cancer is a hormone dependent malignancy. Thy-
roid hormone receptors affect both the normal breast cell
differentiation and breast cancer cell proliferation, with
effects of thyroid hormones similar to those caused by
estrogens [1,2]. Relationship between thyroid diseases,
such as nodular hyperplasia, hyperthyroidism and thyroid
cancer, with breast cancer was demonstrated in several
studies [3-6]. However, ambiguous results concerning the* Correspondence: MKarbownik@hotmail.com
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reproduction in any medium, provided the orabove association have been recently summarized [7]. In
contrast, hypothyroidism due to Hashimoto's thyroiditis
was documented as a protective factor against breast can-
cer [8-10], but also this observation was not confirmed in
other sources [11].
Graves' disease, one of the thyroid autoimmune diseases,
is characterized – in its typical form – by hyperthyroidism
with laboratory results of decreased thyrotropin (TSH)
level, increased free thyroxine (FT4) and/or free triiodo-
thyronine (FT3) levels, detectable TSH receptor (TSHR)
stimulating antibodies (TSHRAb), usually positive thyroid
peroxidase antibodies (TPOAb) and thyroglobulin anti-
bodies (TgAb) [12]. An exclusive diagnostic feature of
Graves' disease is the presence of TSHRAb. The ligandl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tissue [13].
Only limited aspects of potential association between
Graves’ disease and breast cancer have been postulated
[14,15], whereas the exact mechanism has not been identi-
fied [16]. Genetic, environmental and molecular pathways
of both female predominant diseases have been described,
and integrated analysis of the above entities provides
opportunity to identify the potential relevant common
etiological mechanisms [17]. The potential relationship
between antithyroid autoantibodies and breast cancer has
not been clearly documented, as the elevated serum levels
of TPOAb and TgAb in patients with breast cancer,
detected in some studies [18-21], have not been confirmed
elsewhere [22,23]. Moreover, no conclusive research has
been undertaken concerning significance of TSHRAb in
patients with breast cancer [24].
The aim of the study was to evaluate the prevalence of
breast cancer or benign breast tumors in patients with
Graves’ disease and to analyze a possible relationship
between Graves’ disease and these two groups of breast
diseases with emphasis to epidemiology and laboratory
findings.
Patients and methods
Retrospective clinical details of 2003 women, who were
hospitalized for endocrine disorders in the Department
of Endocrinology and Metabolic Diseases at the Polish
Mother’s Memorial Hospital – Research Institute in
Lodz within a 3-year period between 2002 and 2005,
were retrieved from the hospital records following the
internal audit approval. Inclusion criteria were female
adults. Exclusion criteria were all oncological conditions
other than breast neoplasia and thyroid disorders other
than Graves’ disease, such as nodular goiter, thyroid can-
cer, autoimmune thyroiditis (AIT), etc.
After exclusion, 1686 women aged 36.48 ± 15.95 years
were enrolled to the study (Table 1). Two studied groups
consisted of 47 patients with benign breast tumors
(BBT), aged 46.27 ± 14.18 years and 9 patients with
breast cancer (BC), aged 54.55 ± 9.60 years. Therefore,
1630 women hospitalized for several non-oncological
diseases and without thyroid diseases other than Graves’
disease (polycystic ovary syndrome, primary infertility,Table 1 Clinical characteristics of patients with breast cancer,
Parameter Clinical characteristics
BC BBT C
Patients – No (%) 9 (0.53%) 47 (2.78%) 1630 (96.6%
Age – yr (mean ± SD) 54.55 ± 9.60 46.27 ± 14.18 36.10 ± 15.89
Graves’ disease – No (%) 3 (33.3%) 6 (12.7%) 111 (6.8%)
Clinical characteristics of patients with breast cancer (BC), patients with benign brea
Statistical evaluation was done by an unpaired Student’s t-test (for age) or by the tw
occurrence); ns, non-significant.osteopenia, osteoporosis, obesity, dwarfism, anorexia,
atherosclerosis, cardiomyopathy, dyslipidemia, hirsutism,
hypertension, ischemic heart disease, gastric ulcer, meta-
bolic syndrome or diabetes of any type) were considered
as a control group (C) with an average age of 36.10 ±
15.89 years.
Because of the relatively high age range of women with
breast cancer and to analyze the cause-effect relation,
age-matched groups of patients and healthy women
could not be investigated in all stages of the analysis.
Therefore, the predictors of breast cancer were analyzed
in the age-matched group of 499 patients, including 9
patients with BC aged 54.55 ± 9.60 years and 490 control
individuals (C) aged 53.86 ± 8.88 years (p > 0.05).
The following parameters were recorded with the use of
the data analysis program, designed by one of co-authors
of the study (P.S.): age and laboratory parameters, i.e. TSH,
FT4, FT3, TSHRAb, TgAb and TPOAb. The following
diagnoses were considered: Graves’ disease, benign breast
tumors (BBT) and breast cancer (BC). The normal ranges
of the laboratory tests in our hospital are: TSH (0.27–4.2
mIU/L), FT4 (0.93–1.7 ng/dL), FT3 (1.8–4.6 pg/mL),
TPOAb (<35 IU/mL), TgAb (<115 IU/mL) and TSHRAb
(<1.8 IU/mL).
The data were statistically analyzed using an unpaired
Student’s t-test – for continuous variables. The two-sided
ratio comparison test was used to evaluate the frequency
of events. Univariate logistic regression analysis, followed
by multivariate logistic regression analysis, was used to de-
termine which continuous variable might have predicted
breast cancer or benign breast tumors. The χ2 test of in-
dependence was used to determine, which dichotomized
variable might have predicted breast cancer or benign
breast tumors. The results are presented as mean ± stand-
ard deviation (SD). Statistical significance was determined
at the level of p < 0.05.Results
Statistically significant differences were found in age
distribution between patients with breast cancer (BC)
and control group (C), as well as between women with
benign breast tumors (BBT) and control group (C)
(Table 1). However, there were no statistical differencesbenign breast tumors, Graves’ disease and in controls
Statistical analysis
All patients p (BC vs. BBT) p (BC vs. C) p (BBT vs. C)
) 1686 (100%) ns <0.0001 <0.0001
36.48 ± 15.95 ns 0.0005 <0.0001
120 (7.1%) ns 0.0025 ns
st tumors (BBT) and controls (C) and the occurrence of Graves’ disease.
o-sided ratio comparison test (for no. of patients and for Graves’ disease
Table 2 Graves’ disease as the dichotomized determinant of breast cancer or benign breast tumors
Dichotomized
determinant
Association with BC (n = 9) Association with BBT (n = 47)
χ2 p χ2 p
Graves’ disease (n = 120) 9.41 0.0021 2.33 ns
χ2 test of independence analysis of the dichotomized determinant (i.e. Graves’ disease occurrence) of breast cancer (BC) or of benign breast tumors (BBT),
performed in all patients; ns, non-significant in all patients.
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tumors (BBT) and patients with breast cancer (BC).
Graves’ disease was diagnosed on the basis of clinical
findings and the presence of TSHRAb in 120 (7.11%) fe-
male patients aged 41.65 ± 15.19 years. Graves’ disease
coexisted more frequently with breast cancer (p = 0.0021),
but not with benign breast tumors (p > 0.05) (Table 2).
In breast cancer patients, the mean values for TSH were
1.724 ± 3.629 mU/L and they did not differ significantly
from those in controls (2.12 ± 5.41 mU/L) and from those
in patients with benign breast tumors (1.35 ± 0.89 mU/L)
(Figure 1). In turn, FT4 was 1.283 ± 0.427 ng/dL in pa-
tients with breast cancer and did not differ significantly
from levels found either in controls (1.34 ± 1.93 ng/dL) or
in women with benign breast tumors (1.30 ± 0.67 ng/dL).
In patients with breast cancer, FT3 was 2.882 ± 1.617 pg/mL
and was similar to controls (3.33 ± 1.91 pg/mL) and to pa-
tients with benign breast tumors (3.54 ± 1.65 pg/mL).
When levels of thyroid antibodies were compared
among three groups of patients, the following differences
were found. The mean values of serum TSHRAb were
25.65 ± 20.29 IU/ml in breast cancer patients, they were
significantly lower in controls (4.83 ± 8.19 IU/ml, p =
0.0006), and were lower in patients with benign breast
tumors (8.52 ± 14.04 IU/ml), but the differences between
BC and BBT or between BBT and controls did not reach
statistical significance (Figure 2). Serum concentrationsFigure 1 Levels of hormones in patients with breast cancer,
with benign breast tumors and in controls. Levels of hormones
in: patients with breast cancer (BC), patients with benign breast
tumors (BBT) or controls (C), expressed as mean ± SD; Statistical
analysis with Student’s unpaired t-test; ns, non-significant.of TgAb in patients with breast cancer were 1120.8 ±
1914.9 IU/ml and were considerably higher than in con-
trols (241.4 ± 565.0 IU/ml, p = 0.0100) and markedly
higher than in patients with benign breast tumors
(191.7 ± 267.1 IU/ml, p = 0.0443) (Figure 3). In turn,
TPOAb in patients with breast cancer were at level of
157.8 ± 294.8 IU/ml and were similar to control group
(135.7 ± 206.0 IU/ml, p > 0.05) and to benign breast tu-
mors (178.9 ± 221.9, p > 0.05).
Several parameters, such as hormones and antibodies
concentrations were submitted to a univariate and a
multivariate logistic regression model. The purpose of
the model was to determine which of those continuous
variables might predict breast cancer or benign breast
tumors either in the entire group of female patients or
in age-matched groups. No predictive value for any of
the examined hormones and for TPOAb was docu-
mented at univariate regression analysis in the entire
group of patients (Table 3). In opposite, breast cancer pre-
dictive value for TSHRAb (OR = 1.10, 95% CI = 1.01-1.20,
p = 0.0222) and TgAb (OR = 1.00, 95% CI = 1.00-1.01, p =
0.0377) was found at univariate regression analysis in the
entire group of patients. Thus, TSHRAb and TgAb could
be theoretically considered as positive risk factors for
breast cancer. However, both above determinants lost their
predictive value at multivariate analysis. In turn, meticu-
lous logistic regression analysis, based on the age-matchedFigure 2 Levels of TSHRAb in patients with breast cancer, with
benign breast tumors and in controls. Levels of TSHRAb in:
patients with breast cancer (BC), patients with benign breast tumors
(BBT) or controls (C), expressed as mean ± SD; Statistical analysis with
Student’s unpaired t-test; ns, non-significant.
Figure 3 TgAb and TPOAb levels in patients with breast cancer,
benign breast tumors and in controls. Levels of TgAb and TPOAb
in: patients with breast cancer (BC), patients with benign breast
tumors (BBT) or controls (C), expressed as mean ± SD; Statistical
analysis with Student’s unpaired t-test; ns, non-significant.
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vealed that TSHRAb is the only variable possessing
predictive value for breast cancer (OR = 1.09, 95% CI =
1.00-1.20, p = 0.0368) (Table 4). No other predictors of
breast cancer or benign breast tumors were documented
in our series.
Distribution of breast tumors in relation to age inter-
vals and in comparison to Graves’ disease is presented in
Figure 4. A shift between diagnosis of Graves’ disease
and breast cancer was observed. Peak incidence of
Graves’ disease was seen in patients at age of about
35 years and the lowest frequency was observed at age
of about 45 years, whereas peak level of breast cancer
diagnosis were noted at about 65 years, and the lowest
frequency at about 75 years. In contrast, we observed no
similar distribution trends in relation to age intervals
between benign breast tumors and breast cancers or be-
tween benign breast tumors and Graves’ disease.Table 3 Hormone and autoantibody concentrations as determ
Parameter Association with BC (n =
Univariate logistic regression Multiv
OR 95% CI p OR
TSH (mIU/L) 0.97 0.75-1.26 ns
FT4 (ng/dL) 0.96 0.42-2.21 ns
FT3 (pg/mL) 0.48 0.71-1.82 ns
TSHRAb (IU/mL) 1.10 1.01-1.20 0.0222 0.92
TgAb (IU/mL) 1.00 1.00-1.01 0.0377 0.99
TPOAb (IU/mL) 1.00 0.99-1.01 ns
Univariate and multivariate logistic regression analysis of the univariate determinan
breast benign tumor (BBT), performed in all patients (n = 1686); OR, odds ratio; CI, cDiscussion
Mammary gland is derived from iodide-concentrating
ectoderm [17]. Breast functions are similar to the thyroid
gland in relation to the absorption capacity of iodide for
use as a milk ingredient during lactation [4,25]. Altered
thyroid hormonal function due to abnormal iodine uptake
has an impact on incidence of iodine deficiency disorders
(IDD) [25], autoimmune diseases and could possibly affect
cancer development. Increased intake of iodine is consi-
dered as a protective factor against the occurrence of
breast cancer [26]. In conformity, low levels of iodine were
described in the breast cancer tissues as compared to nor-
mal breast tissue or benign breast tumors [27].
Uptake of serum iodide into the breast alveolar and duc-
tular cells happens in the mechanism of active transport via
the glycoprotein – Na+/I-symporter (NIS) [28]. The expre-
ssion of NIS occurs in 80% to 90% of breast cancer cases
and, thus, symporter could be potentially used in the radio-
isotope breast imaging with 125I (alternatively 99mTc) and
in the breast cancer treatment with 131I (alternatively 188Re)
[13], following administration of stimulants enhancing NIS
expression [29,30].
Assessment of hormonal thyroid function in breast can-
cer patients was assessed in our study with measurement
of TSH, FT4 and FT3 levels and we found no differences
among breast cancer patients, women with benign breast
tumors and female controls. However, limited short-term
hormone observations cannot be interpreted in relation to
the long-term cancer development because of the change-
able thyroid activity affected by several extrinsic and intrin-
sic factors. In turn, concerning the impact of autoimmune
diseases on breast cancer incidence, we confirmed the high
prevalence of breast cancer in patients with Graves' disease
(Table 2).
Thyroid antibodies in the autoimmune thyroid disorders
could interact with the receptors on breast tumors and
thus they were previously designated as precursors for the
coincidence of mammary and thyroid disorders [31].
Autoantigens, TPO in the thyroid and lactoperoxidases ininants of breast cancer or benign breast tumors
9) Association with BBT (n = 47)
ariate logistic regression Univariate logistic regression
95% CI p OR 95% CI p
- 1.20 0.92-1.55 ns
1.01 0.78-1.31 ns
0.95 0.81-1.11 ns
0.66-1.28 ns 0.97 0.91-1.03 ns
0.99-1.00 ns 1.00 0.99-1.00 ns
- 1.00 0.99-1.00 ns
ts (such as hormone and autoantibody concentrations) of breast cancer (BC) or
onfidence interval; ns, non-significant.
Table 4 Hormone and autoantibody concentrations as
breast cancer or benign breast tumors determinants, in
age-matched groups
Parameter Association with BC (n = 9)
OR 95% CI p
TSH (mIU/L) 0.96 0.77-1.21 ns
FT4 (ng/dL) 0.92 0.32-2.67 ns
FT3 (pg/mL) 0.69 0.29-1.62 ns
TSHRAb (IU/mL) 1.09 1.00-1.20 0.0368
TgAb (IU/mL) 1.00 0.99-1.00 ns
TPOAb (IU/mL) 0.99 0.99-1.00 ns
Univariate logistic regression analysis of the univariate determinants (such as
hormone and autoantibody concentrations) of breast cancer (BC) or breast
benign tumor (BBT), performed in the age-matched groups of patients
(n = 499); OR, odds ratio; CI, confidence interval; ns, non-significant.
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duce iodoproteins [32], as they catalyze H2O2 production
to oxidize I- [33]. Previously reported potential association
between TPOAb or TgAb and breast cancer was arguable
and the results were summarized in Table 5 [4,18,34-36].
The presence of TPOAb was previously described as a
prognostic index of a more favorable outcome in patients
with breast cancer, with similar importance to the tumor
size and to the axillary nodal status [37]. In our study,
TPOAb levels were similar among the three analyzed
groups. In turn, TgAb levels were higher in our series in
patients with breast cancer comparing to controls and to
patients with benign breast tumors. However, the ligand
for TgAb, thyroglobulin (Tg), has antigenicity affected by
the iodine content within the protein [18,38], and thus
TgAb are present non-specifically in different diseases
coexisting with the altered iodine intake [39]. More im-
portantly, TgAb can be also found in patients with chronicFigure 4 Trends in occurrence of breast cancer, benign breast tumors
breast tumors (BBT) in relation to age intervals and in comparison to Gravedisorders not involving thyroid [40] or even in healthy pa-
tients without any thyroid disease [41]. Thus, clinical im-
pact of the elevated concentrations of TgAb is unreliable,
as they were detected non-specifically to thyroid diseases
or breast cancer.
Relationship between incidence of benign breast tu-
mors and thyroid diseases with the increased levels of
TgAb and TPOAb in serum has been also proposed
[42]. Previous report documented the increased level
of TPOAb in 28% of women with benign fibrocystic
mastopathies and 80% had thyroid hypertrophy [21,43].
In contrary, we did not observe any association between
Graves’ disease, hormones or antibodies concentrations
and occurrence of benign breast tumors.
Interaction between thyroid and breast cancer can occur
in the mechanism involving TSHR, common in the adi-
pose breast tissue [35]. Under physiological conditions,
TSH via TSHR stimulates growth, differentiation and
function of the thyroid cells [4,44]. This receptor is a tar-
get for THSRAb in Graves’ disease. It should be stressed
that TSHR expression is common in breast cancer, with
higher prevalence in low-grade breast cancer [13]. The
clinical significance of the serum TSHRAb in relation to
breast cancer and Graves' disease was unresolved in the
previous observations [6,15]. In our study, TSHRAb levels
were significantly higher in breast cancer comparing to
controls. They were positive determinants of breast cancer
in the univariate logistic regression analysis, which did not
reach statistical significance in multivariate logistic regres-
sion analysis. However, in the analysis of the age-matched
groups of patients, TSHRAb was found to be the only
positive determinant of breast cancer. Therefore, we sug-
gest that TSHRAb can be called a positive predictor for
the subsequent development of breast cancer. However,and Graves’ disease. Distribution of breast cancer (BC) or benign
s’ disease, expressed as linear trends.
Table 5 Summarized previous reports concerning relationship between thyroid diseases and breast cancer or benign breast tumors
Parameter [Previously reported data] (n = number of patients enrolled to study)
[3] (n = 150) [18] (n = 115) [34] (n = 61) [35] (n = 175) [36] (n = 48)
BC C p BC C p BC C p BC C p BC C p
n 150 100 - 66 49 - 36 100 - 100 75 - 26 22 -
Age-yr means ± SD
(min-max)
63 (38–80) age-matched - 63.5 ± 11.8 68.4 ± 12.8 ns 52.8 ± 10.2 age-matched - 63 (38–80) - - (30–85) age-
matched
-









units μIU/ml mIU/dl μIU/ml μIU/ml μU/ml









units ng/dl pmol/dl pg/ml ng/dl ng/dl
FT3 8.47 ± 0.75 4.48 ± 0.75 ns - 3.58 ± 0.7 3.2 ± 0.6 ns 7.25 ± 0.
75





units pmol/l pg/ml pmol/l pmol/ml




<0.001 12/36 12/100 p < 0.01 - -
units IU/ml kIU/dl Patients’ ratio with positive TgAb









units IU/ml kIU/dl Patients’ ratio with positive TPOAb IU/ml
Diagnosis BC C p BC C p -
Graves’ disease - 0/66 0/49 -
AITD 57/150 17/100 0.001 16/66 8/49 -















Szychta et al. Thyroid Research 2013, 6:8 Page 7 of 8
http://www.thyroidresearchjournal.com/content/6/1/8further prospective research is required on a larger group
of patients to determine unquestionably the significance
of the above association.
Consequently, neutral TSHR antagonists (ligands in-
hibiting receptor activation by agonists), such as NIDDK-
CEB-52, NCGC00242595 and NCGC00229600, could play
a potential role in the breast cancer prophylaxis, acting as
precursors of drugs preventing from TSHRAb activation
in patients with Graves’ disease [45]. Monoclonal anti-
bodies, currently used in experimental studies on the
medical therapeutic intervention in Graves' disease by
vaccination with chemically altered autoantigens, could
selectively deplete specific T lymphocytes subsets and
block the T-cell receptor MHC interaction [46]. Addition-
ally, no reports were found assessing the theoretical sup-
pressive effect of blocking subtype of TSHRAb (causing
hypothyroidism) on breast cancer and thus such clinical
research would be advisable.
As discussed above, reduced iodide concentration, ele-
vated levels of the thyroid hormones and antibodies con-
tributed to an increased risk of breast cancer in previous
reports and in our study. However, some authors sug-
gested also the possible impact of breast cancer on the
thyroid with the resulting increased level of thyroid hor-
mones and the autoimmune response with the detect-
able thyroid antibodies [5]. In our series we found shift
of about 15–20 years between the primary peak of the
diagnosed Graves' disease and the secondary maximal
incidence of breast cancer (Figure 4). However, the ob-
served long shift is partially affected by the fact that par-
ticipants in our study were younger than the general
population of patients with Graves’ disease, as they were
hospitalized due to the more prominent symptoms.
Older patients with usually more subtle clinical course
of Graves’ disease are treated as outpatients [47]. Despite
some possible level of bias, we claim that it is the
Graves’ disease which could contribute to the subse-
quently observed development of breast cancer.
In conclusion, the strong relationship between Graves’
disease and breast cancer is proposed. We suggest that
TSHRAb could be described as a positive determinant
of breast cancer. The present data call attention to the
usefulness of screening for breast cancer in long-term
follow-up of patients with autoimmune thyroid disor-
ders, especially of those with Graves’ disease. Similarly,
screening for autoimmune thyroid disorders should be
performed in patients with nodular breast disease. Add-
itionally, the article draws ideas for further research in
order to develop targeted treatment for more successful
outcome in patients with breast cancer.Competing interests
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